CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

ManremycWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D007239 Infection NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Double-blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of the Manremyc® Food Supplement to Prevent SARS-CoV-2 Infection

The purpose of this study is to assess the efficacy of Manremyc® food supplement for reduce the incidence of SARS-CoV-2 infection in a high risk population, as healthcare workers.

NCT04452773 COVID19 Dietary Supplement: Manremyc Dietary Supplement: Placebo
MeSH:Infection

Primary Outcomes

Description: % of positive serology at the end of the study or positive PCR test in the course of routine clinical practice

Measure: Documented cumulative incidence of SARS-CoV-2 infection

Time: up to 4 months

Secondary Outcomes

Description: Number of days Documented as sick leave for SARS-CoV-2

Measure: Documented sick leave for SARS-CoV-2

Time: up to 4 months (cumulative)

Description: Number of days off work due to the quarantine imposed as a consequence to have acute respiratory symptoms, fever or infection documented by SARS-CoV-2

Measure: days off work due to the quarantine

Time: up to 4 months

Description: Number of days in quarantine imposed by close contact outside the center with SARS-CoV-2 positive

Measure: Quarantine imposed by close contact outside the center with SARS-CoV-2 positive

Time: up to 4 months

Description: Number of days of self-reported fever (≥38 ºC)

Measure: Fever

Time: Up to 4 months

Description: Cumulative incidence of self-reported acute respiratory symptoms

Measure: Cumulative incidence of self-reported acute respiratory symptoms

Time: up to 4 months

Description: Number of days of self-reported acute respiratory symptoms

Measure: Number of days of self-reported acute respiratory symptoms

Time: up to 4 months

Description: Number of participants with pneumonia confirmed by X-ray

Measure: Incidence of pneumonia

Time: up to 4 months

Description: Cumulative incidence of death from documented SARS-CoV-2 infection

Measure: Cumulative incidence of death from documented SARS-CoV-2 infection

Time: Up to 4 months

Description: Cumulative incidence of admissions to intensive care unit for documented SARS-CoV-2 infection

Measure: Incidence of admission to ICU

Time: Up to 4 months

Description: Number of days admitted to the ICU for documented SARS-CoV-2 infection

Measure: Days in IUC

Time: Up to 4 months

Description: Cumulative incidence of need for mechanical ventilation due to documented SARS-CoV-2 infection

Measure: Incidence of mechanical ventilation

Time: Up to 4 months

Description: Cumulative incidence of hospital admissions for documented SARS-CoV-2 infection

Measure: Incidence of hospital admissions

Time: Up to 4 months

Description: Number of days of hospitalization for documented SARS-CoV-2 infection

Measure: Days of hospitalization

Time: Up to 4 months

Description: Levels of IgG

Measure: Levels of IgG

Time: Up to 4 months

Description: Levels of IgM

Measure: Levels of IgM

Time: Up to 4 months

Description: Levels of SARS-CoV-2 antibodies at the end of the study period

Measure: Levels of SARS-CoV-2 antibodies at the end of the study period

Time: Up to 4 months

Other Outcomes

Description: All adverse events reported by the subjects, both serious and non-serious, will be collected. All events related to a SARS-CoV-2 infection will be exempted from collection, as they will be collected as part of the associated symptoms

Measure: AEs

Time: Up to 4 months

Description: All thoseAdverse Events that lead to hospitalization of the patient, that endanger his life or cause or may cause death.

Measure: SAEs

Time: Up to 4 moths

No related HPO nodes (Using clinical trials)